At the news
? BEARISHIMPACT 5/10 6-K filed Jul 27, 2026 at 06:10 ET
Sanofi reported two items in this 6-K: (1) a reorganization of its Executive Committee effective September 1, 2026, and (2) the discontinuation of amlitelimab (OX40-ligand mAb) development in moderate-to-severe atopic dermatitis, deciding not to submit for global regulatory reviews. The pipeline setback is the most material item, though Sanofi explicitly stated it is not amending its full-year 2026 guidance. The executive changes are routine and neutral for the stock.
- Sanofi discontinued clinical development of amlitelimab in moderate-to-severe atopic dermatitis and will not submit for global regulatory reviews.
- The decision was based on the assessment that amlitelimab would not represent a meaningful improvement to the standard of care in AD.
- Sanofi is not amending its full-year 2026 guidance as a result of this announcement.
- A phase 2 study of amlitelimab in celiac disease is ongoing, with data expected in H2 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access